Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Prostatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Jun 2018 Status changed from not yet recruiting to recruiting.
- 29 May 2018 Planned initiation date changed from 9 May 2018 to 14 Jun 2018.